InsiderClue
Stocks · Health care · Pharmaceutical Preparations

BIOHARVEST SCIENCES INC.

BHST Clue Score59
British Columbia, Canada Fiscal year ends December CIK 0001723464
$1.62 -2.41% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.62 +478.36% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 8 Mar 2019. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue12.7Operating income−10.0Net income−12.6Fiscal year 2024Revenue25.2 +98.8%Operating income−7.0Net income−12.9Fiscal year 2025Revenue34.5 +37.0%Operating income−5.6Net income−11.1
FY2023FY2024FY2025
Revenue 12.7 25.2 34.5
Growth +98.8% +37.0%
Operating income −10.0 −7.0 −5.6
Net income −12.6 −12.9 −11.1
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2023Gross margin44.5%Operating margin−78.6%Net margin−99.1%Free cash flow margin−78.9%Fiscal year 2024Gross margin55.4%Operating margin−27.7%Net margin−51.3%Free cash flow margin−37.8%Fiscal year 2025Gross margin59.3%Operating margin−16.2%Net margin−32.3%Free cash flow margin−27.8%
FY2023FY2024FY2025
Gross margin 44.5% 55.4% 59.3%
Operating margin −78.6% −27.7% −16.2%
Net margin −99.1% −51.3% −32.3%
Free cash flow margin −78.9% −37.8% −27.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−8.5Capital expenditure−1.5Free cash flow−10.0Fiscal year 2024Operating cash flow−6.7Capital expenditure−2.8Free cash flow−9.5Fiscal year 2025Operating cash flow−7.2Capital expenditure−2.4Free cash flow−9.6
FY2023FY2024FY2025
Operating cash flow −8.5 −6.7 −7.2
Capital expenditure −1.5 −2.8 −2.4
Free cash flow −10.0 −9.5 −9.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash and securitiesTotal debt
Fiscal year 2023Cash and securities5.4Total debt0.0Net cash (debt)5.4Shareholders’ equity−14.9Fiscal year 2024Cash and securities2.4Total debt3.9Net cash (debt)−1.5Shareholders’ equity1.3Debt to equity2.94Fiscal year 2025Cash and securities23.0Total debt0.1Net cash (debt)22.9Shareholders’ equity25.4Debt to equity0.01
FY2023FY2024FY2025
Cash and securities 5.4 2.4 23.0
Total debt 0.0 3.9 0.1
Net cash (debt) 5.4 −1.5 22.9
Shareholders’ equity −14.9 1.3 25.4
Debt to equity n/a 2.94 0.01

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
12.7 25.2 34.5
Growth +98.8% +37.0%
7.0 11.2 14.0
5.6 13.9 20.5
Growth +147.5% +46.9%
3.4 4.8 5.3
4.5 4.4 4.9
−10.0 −7.0 −5.6
Growth
−12.6 −12.9 −11.1
0.0 −0.0 −0.1
−12.6 −12.9 −11.1
Growth
Per share
−0.93 −0.80 −0.60

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 3 of 3 years on file.